AstraZeneca expects $80 billion revenue by 2030, with rising stock post Q4 earnings beat.
On Tuesday morning, AstraZeneca's stock experienced a moderate increase due to stronger-than-anticipated sales and profits in the fourth quarter. The company reconfirmed its long-term outlook, projecting a revenue of $80 billion by 2030, prior to an anticipated period of significant growth in 2026.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments